2020
DOI: 10.3892/or.2020.7553
|View full text |Cite
|
Sign up to set email alerts
|

Vascular endothelial growth factor receptor 1 in glioblastoma‑associated microglia/macrophages

Abstract: The anti-vascular endothelial growth factor-A (VEGF-A) monoclonal antibody (mAb) bevacizumab is an FDA-approved monotherapy for the treatment of recurrent glioblastoma (GB), a highly angiogenic and infiltrative tumour. However, bevacizumab does not increase overall survival and blockade of VEGF-A/VEGF receptor (VEGFR)-2 signal transduction is associated with severe adverse effects due to inhibition of physiological angiogenesis. Conversely, VEGFR-1 does not play a relevant role in physiological angiogenesis in… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
10
0

Year Published

2020
2020
2022
2022

Publication Types

Select...
5
2

Relationship

2
5

Authors

Journals

citations
Cited by 12 publications
(10 citation statements)
references
References 44 publications
0
10
0
Order By: Relevance
“…For exploring the mechanism through which miR-214 affects the properties of CSCC cells, we identi ed that VEGFA and Bcl-2 are two targets of miR-214 and could predict dismal survival of patients with CSCC. The Cancer Genome Atlas database disclosed that upregulation of VEGFA was related with a signi cant decline in overall survival for patients with glioblastoma [17]. Further, we discovered that the OD values, number of migration and invasion rates were elevated in A431 and SCC13 cells harboring overexpressing miR-214 and VEGFA/Bcl-2 compared to those cells overexpressing miR-214 only.…”
Section: Discussionmentioning
confidence: 79%
“…For exploring the mechanism through which miR-214 affects the properties of CSCC cells, we identi ed that VEGFA and Bcl-2 are two targets of miR-214 and could predict dismal survival of patients with CSCC. The Cancer Genome Atlas database disclosed that upregulation of VEGFA was related with a signi cant decline in overall survival for patients with glioblastoma [17]. Further, we discovered that the OD values, number of migration and invasion rates were elevated in A431 and SCC13 cells harboring overexpressing miR-214 and VEGFA/Bcl-2 compared to those cells overexpressing miR-214 only.…”
Section: Discussionmentioning
confidence: 79%
“…Therefore, bevacizumab should be combined with therapies targeting GAMs to prevent their expansion. In this regard, by analyzing surgical specimens collected from glioblastoma patients, we recently demonstrated that GAMs expressed VEGFR-1 and the percentage of VEGFR-1 positive GAMs was higher in the tumor tissue than in the surrounding parenchyma [154]. Thus, VEGFR-1 targeting might synergize with anti-VEGF-A therapies counteracting the rebound-proangiogenic effects mediated by GAMs and delaying resistance development.…”
Section: Glioblastomamentioning
confidence: 99%
“…[38] Looking at the current target antigens in clinical trials running for advanced stage melanoma patients, for instance, we can also observe that these target antigens are not exclusively expressed on melanocytes or melanoma cells ( TA B L E 1 Clinical trials for melanoma using chimeric antigen receptors (as of April 21st, 2020) clinical trials include, for example the tyrosine-protein kinase c-MET and vascular endothelial growth factor (VEGF).While c-MET is normally expressed by cells of epithelial origin (healthy and malignant tissues), [39][40][41] VEGF activity is restricted mainly to cells of the vascular endothelium, although it is known that it also has effects on other cell types, for example monocytes and macrophages. [42][43][44] Thus, the results of these clinical studies must first be evaluated in order to be able to decide-apart from the clinical benefit-if the use of these antigens is safe or if it leads to severe on-target/off-tumor toxicities.…”
Section: The Ide Al Targ E T Anti G Enmentioning
confidence: 99%
“…Target antigens in these clinical trials include, for example the tyrosine‐protein kinase c‐MET and vascular endothelial growth factor (VEGF).While c‐MET is normally expressed by cells of epithelial origin (healthy and malignant tissues), [ 39‐41 ] VEGF activity is restricted mainly to cells of the vascular endothelium, although it is known that it also has effects on other cell types, for example monocytes and macrophages. [ 42‐44 ] Thus, the results of these clinical studies must first be evaluated in order to be able to decide—apart from the clinical benefit—if the use of these antigens is safe or if it leads to severe on‐target/off‐tumor toxicities.…”
Section: The Ideal Target Antigenmentioning
confidence: 99%